We used patient-derived tumor xenografts grown in immune compromised NOD SCID mice to determine the efficacy of TCN→PAC compared to PAC→TCN on tumors of human origin that also overexpress ZNF217 (Figure 4A). Here, ZNF217 is linked to neoplasm.